Displaying One Session

Room 310 Mini Oral session
Date
24.11.2018
Time
09:00 AM - 09:45 AM
Location
Room 310
Chairs
  • Deme Karikios
  • Bishal Gyawali
Mini Oral - Public policy Mini Oral session

396O - A multi-center, randomized, double-blind, parallel, two-group Phase III trial on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in first-line treatment of non-squamous non-small cell lung cancer

Presentation Number
396O
Lecture Time
09:00 AM - 09:05 AM
Speakers
  • Baohui Han
Location
Room 310, Singapore, Singapore, Singapore
Date
24.11.2018
Time
09:00 AM - 09:45 AM
Authors
  • Baohui Han
  • Kai Li
  • Tianqing Chu
  • Minghong Bi
  • Helong Zhang
  • Yan Yu
  • Jianhua Shi
  • Xiaochun Zhang
  • Zhendong Chen
  • Cuicui Han
  • Tao Bai

Abstract

Background

QL1101 is a biosimilar molecule of bevacizumab (BEV, Avastin), a monoclonal antibody (mAb) that binds and inhibits vascular endothelial growth factor (VEGF). The main purpose of the study was to evaluate whether the effectiveness of QL1101 is equivalent to that of Avastin; the secondary purpose is safety and immunogenicity.

Methods

The study (NCT03169335) planned to recruit 512 patients with locally metastatic or recurrent non-squamous cell non-small cell lung cancer to QL1101 (test group) or Avastin (control group) in combination with paclitaxel/carboplatin (paclitaxel 175mg/m2, carboplatin AUC=5) at a 1:1 ratio. QL1101 or Avastin (15mg/kg, respectively) combined with chemotherapy, every 3 weeks as one treatment cycle for 6 cycles, followed by QL1101 single-drug maintenance treatment until disease progression, intolerable toxicity, initiation of other treatment, loss to follow-up or death. The primary endpoint was the best objective response rate (ORR) evaluated by the blind independent imaging review committee at week 18.

Results

A total of 675 subjects were screened and 532 were eventually treated, including 266 in the trial group and 266 in the control group. At week 18, the ORR of the QL1101 group and Avastin group, evaluated by the blind independent imaging review committee, was 52.26% (CR:0, PR:139) and 56.02% (1 cases CR, 148 PR), respectively. Risk ratio (RR) value was 0.917 (90% CI, 0.807-1.043), which met the prespecified equivalence margins (0.75-1.33). The incidence of treatment-related adverse events and immunogenicity of the two groups was similar, and no neutralizing antibodies were detected.

Conclusions

QL1101 and Avastin are equivalent in clinical efficacy in non-squamous cell non-small cell lung cancer patients, and the safety profile (including immunogenicity) is similar. There are no unexpected serious adverse reactions.

Clinical trial identification

NCT03169335.

Legal entity responsible for the study

Professor Baohui Han.

Funding

Qilu Pharmaceutical Co., Ltd.

Disclosure

All authors have declared no conflicts of interest.

Collapse
Mini Oral - Public policy Mini Oral session

397O - Adolescents and Young Adults with Cancer Care in Asia: The Joint ESMO/SIOPE/SIOP ASIA survey

Presentation Number
397O
Lecture Time
09:05 AM - 09:10 AM
Speakers
  • Rashmi Dalvi
Location
Room 310, Singapore, Singapore, Singapore
Date
24.11.2018
Time
09:00 AM - 09:45 AM
Authors
  • Rashmi Dalvi
  • Chi-kong Li
  • Kan Yonemori
  • Hany Ariffin
  • Chuhl Joo Lyu
  • Mohamad Farid
  • Julieta Rita Nacalaban Gonzales-Santos
  • Qing Zhou
  • Stefan Bielack
  • Laurence Brugieres
  • Anne Blondeel
  • Samira Essiaf
  • Fedro A. Peccatori
  • Svetlana Jezdic
  • Daniel Stark
  • Jean-Yves Douillard
  • Emmanouil Saloustros
  • Giannis Mountzios

Abstract

Background

Adolescents and young adults (AYA) with cancer require dedicated management that encompasses both adult and paediatric cancer services. Following the European survey, the European Society for Medical Oncology (ESMO), the European Society for Paediatric Oncology (SIOPE) and the Asian Society for Paediatric Oncology (SIOP-ASIA) ran a tailored one to identify availability, access and disparities in AYA cancer care across Asia.

Methods

A link to an online survey was sent to healthcare professionals (HCPs) in Asia interested in AYA cancer care. Questions covered the demographics and training of HCPs, definition of AYA, availability and access to AYA-specialised centres, trends, habits, disparities and challenges encountered in the management of cancer in AYA.

Results

In total, 268 responses were received from 22 Asian countries. Among respondents, 22% reported being trained to treat both adults and children. There was a striking variation in the definition of AYA (median lower age 15 years, median higher age 29 years). The majority of the respondents did not have access to specialised cancer services (78%) and were not aware of any research initiatives or clinical trials for AYA (73%). Over two-thirds were able to refer their patients for psychological (69%) and/or nutrition support (69%); however, more than half did not have access to a social worker (60%), education mentor (55%), or age-specific nurse specialist (63%). Most advised their patients on a healthy lifestyle after cancer treatment; nevertheless, 46% did not ask their patients regarding smokeless tobacco habits and only 49% referred smokers to a smoking cessation service. Furthermore, 29% did not promote HPV vaccination for girls and 17% did not promote HBV vaccination for high-risk individuals. In terms of funding, 69% reported governmental insurance coverage, albeit 65% reported also at least partially self-paid. Almost half reported treatment non-compliance or abandonment (47%), attributed to financial and family problems (72%), loss to follow-up (74%) and seeking alternative treatments (77%).

Conclusions

Lack of access to and suboptimal delivery of AYA-specialised cancer care services pose major challenges across Asia.

Legal entity responsible for the study

European Society for Medical Oncology (ESMO).

Funding

European Society for Medical Oncology (ESMO).

Disclosure

S. Bielack: Fees for participation at Advisory boards: Pfizer, Bayer, Lilly, Novartis, Isofol, Sensorion. F.A. Peccatori: Fees: Roche, AstraZeneca, Clovis, Ipsen. D. Stark: Research grant income in AYA cancer: The National Institute for Health Research, Cancer Research UK, the Teenage Cancer Trust; Research support: Pharmamar Inc and AstraZeneca Inc. All other authors have declared no conflicts of interest.

Collapse
Mini Oral - Public policy Mini Oral session

398O - The Prevalence of Breast Tumor: An Indonesia Non Communicable Disease Survey

Presentation Number
398O
Lecture Time
09:10 AM - 09:15 AM
Speakers
  • Sri Idaiani
Location
Room 310, Singapore, Singapore, Singapore
Date
24.11.2018
Time
09:00 AM - 09:45 AM
Authors
  • Sri Idaiani
  • Delima Delima

Abstract

Background

In 2016, the Ministry of Health conducted a national health survey focusing on breast tumors and cervical pre-cancerous lesion. The aim of this study was to obtain information on breast tumors in women in Indonesia.

Methods

The survey was conducted from July to August 2016 in the urban area because of the health resources distribution considerations. Thirty-four provinces consisting of 76 districts were involved in this survey. The sampling frame used multistage sampling. The first step was to choose districts by probability proportional to size (PPS) to the urban household. The second step was to choose census blocks by PPS to common households. The third was to choose 50 census buildings by systematic sampling. The fourth step was to choose the selected household by random sampling within the census building. The inclusion criteria were 30-64-year-old women, agreement to participate in this study, not pregnant or in the first 6 month breastfeeding period. To examine breast tumors the clinical breast examination (CBE) was conducted by general doctor, midwife, or nurse that had been trained by MOH. The enumerator team visited and verified the household then selected eligible women in selected households. The selected women were invited to primary health care center (PHC) to receive CBE. Data were analyzed using weighting as a survey procedure. The statistical program used was SPSS version 21.

Results

Total participating subjects were 38,749 from 70,000 targeted numbers (response rate was 62, 5%). The breast tumor prevalence was 8.1%; 95% CI 7.4-8, 8%. We found higher prevalence in 35-44 year-old women, those who had never married, had higher education, and were in work.

Conclusions

CBE is a screening tool for breast cancer in Indonesia, therefore the government should prepare the availability of further examination i.e. breast ultrasonography and or mammography in the hospital for approximately 8.1% women to get the definite diagnosis. The low response rate shows that it is quite difficult to invite women to receive breast examination.

Legal entity responsible for the study

Badan Penelitian dan Pengembangan. Kesehatan, Indonesia Ministry of Health.

Funding

Indonesia Government.

Disclosure

All authors have declared no conflicts of interest.

Collapse
Mini Oral - Public policy Mini Oral session

399O - Analysis of the Current Status of Multidisciplinary Team (MDT) Care for Cancer Patients in Korea

Presentation Number
399O
Lecture Time
09:15 AM - 09:20 AM
Speakers
  • Chi Hoon Maeng
Location
Room 310, Singapore, Singapore, Singapore
Date
24.11.2018
Time
09:00 AM - 09:45 AM
Authors
  • Chi Hoon Maeng
  • Hee Kyung Ahn
  • Sung Yong Oh
  • Bong-Seog Kim
  • Seungtaek Lim
  • Do Yeun Kim

Abstract

Background

The multidisciplinary team (MDT) approach is a cornerstone of optimal cancer care. This study was performed to investigate the current status of MDT-based treatment since the implementation of reimbursement for MDT care, including patient satisfaction with MDT care in Korea.

Methods

We obtained the annual number of cancer patients who have received MDT care since August 2014 from the registry of Heath Insurance Review & Assessment Service (HIRA) (the HIRA Cohort). In addition, patients who received MDT care from August 2014 to May 2017 at four university hospitals in Korea were further characterized clinically, and patient satisfaction was measured using a patient-reported questionnaire for patients who could be evaluated prospectively (the Representative Cohort).

Results

The total number of patients who received MDT care rapidly increased from 2014 to 2016 (2,113 to 9,998 patients) in the HIRA Cohort. The most commonly consulted cancer MDT was that for breast cancer (23.8%), followed by colorectal cancer (19.1%). In the Representative Cohort, the total number of registered patients was 1,032. MDT care was requested by the surgeon more than half the time (55.7%). The main focus of MDT care was decision making for further treatment planning (99.0%). The number of doctors participating in the MDT from each department was usually five (70.0%). The treatment plan changed after MDT care for 17.4% of patients. Among these patients, 359 completed a prospective survey of patient satisfaction with MDT care. The overall satisfaction of MDT care by patients and their families was very high.

Conclusions

The application of MDT care in cancer patients in Korea demonstrated a rapidly growing trend with high patient satisfaction. Further refinement for effective implementation of MDT should be determined within the Korean health care system.

Legal entity responsible for the study

KSMO (Korean Society of Medical Oncology).

Funding

KSMO.

Disclosure

All authors have declared no conflicts of interest.

Collapse
Mini Oral - Public policy Mini Oral session

Discussion

Lecture Time
09:20 AM - 09:40 AM
Speakers
  • Deme Karikios
  • Bishal Gyawali
Location
Room 310, Singapore, Singapore, Singapore
Date
24.11.2018
Time
09:00 AM - 09:45 AM
Authors
  • Deme Karikios
  • Bishal Gyawali